BioSpace News Archive

Roche’s patent dispute with Shire over the new haemophilia drug Hemlibra has escalated, with Shire filing a new motion in a U.S. court that Roche says aims to stop some patients from getting its medicine.

The round was led by Berkshire Partners and TPG Growth, with participation from its co-founders and management team, as well as original investors Oak Investment Partners and J.H. Whitney.

An experimental treatment to address cognitive impairment in pediatric patients diagnosed with the rare disease known as Hunter syndrome failed a key trial, Shire PLC announced this morning.

Confo Therapeutics announced today that it has entered into a research collaboration and license agreement with Roche for the discovery, development and commercialisation of novel, small molecule agonists of an undisclosed GPCR for the treatment of neurological and developmental disorders.

The company has chosen to settle the matter for USD five million.

Araim Pharma today announced the publication of preclinical research performed at the University of Messina, Italy, demonstrating the ability of their lead compound cibinetide to improve wound healing in a diabetic mouse model by accelerating wound closure, promoting blood vessel growth, and increasing the strength of the healing tissue.

The collaboration is part of Boehringer Ingelheim’s RBB initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.

He has organized several gene therapy related conferences worldwide, is a founding member of the American Society for Gene Therapy, and serves on the editorial board for prominent peer-reviewed publications.

ClearPath announced today it has initiated a third research collaboration with Astellas Pharma to combat infections.

MiMedx has reached a mutually agreeable settlement in its lawsuit with former employee, William T. Mills, who voluntarily resigned from MiMedx in January 2017.